Characterisation of Endogenous Peptides Present in Virgin Olive Oil

Eduardo Lopez-Huertas 1, * and Juan M. Alcaide-Hidalgo 2

1 Group of Antioxidants and Free Radicals in Biotechnology, Food and Agriculture, Estación Experimental Zaidín, Consejo Superior de Investigaciones Científicas (CSIC), Profesor Albareda 1, 18008 Granada, Spain
2 Eurecat, Technology Centre of Catalonia, Nutrition and Health Unit, 43204 Reus, Spain; juanmaria.alcaide@eurecat.org

* Correspondence: eduardo.lopezhuertas@eez.csic.es; Tel.: +34-958-181600

Abstract: The low molecular weight peptide composition of virgin olive oil (VOO) is mostly unknown. We aimed to investigate the composition of the endogenous peptides present in VOO, the protein sources from which those peptides originate and their biological activities. A water-soluble extract containing peptides was obtained from VOO. The peptides were separated by size-exclusion using fast protein liquid chromatography, and the low molecular weight fraction (1600–700 kDa) was analysed by nanoscale liquid chromatography Orbitrap coupled with tandem mass spectrometry and de novo sequencing. Nineteen new peptides were identified by Peaks database algorithm, using the available Olea europaea (cv. Farga) genome database. Eight new peptides were also identified by Peaks de novo sequencing. The protein sources of the peptides detected in the database by Peaks DB were identified by BLAST-P search. Seed storage proteins were among the most frequent sources of VOO peptides. BIOPEP software was used to predict the biological activities of peptides and to simulate (in silico) the proteolytic activity of digestive enzymes on the detected peptide sequences. A selection of synthetic peptides was obtained for investigation of their bioactivities. Peptides VCGEAFGKA, NALLCSNS, CPANGFY, CCYSVY and DCHYFL possessed strong ACE-inhibitory and antioxidant activities in vitro. Antioxidant peptides could play a role in VOO quality.

Keywords: virgin olive oil; food peptides; bioactive peptides; peptidomics; angiotensin-converting enzyme; antioxidant

1. Introduction

Virgin olive oil (VOO) is the principal oil consumed by Mediterranean countries [1]. VOO mainly contains fatty acids in the form of triglycerides and also a fraction (1–3%) of minor components, or micronutrients. This fraction primarily consists of polyphenols, tocopherols, sterols, terpenic acids, chlorophyll and carotenoids [2,3], which are transferred from olives to the VOO during its extraction. VOO can be consumed as such after it is produced and does not require refining procedures to eliminate undesirable compounds, therefore these micronutrients remain present in the oil and make a significant contribution to the oil’s quality and healthy properties. For example, VOO antioxidant compounds, such as certain polyphenols (hydroxytyrosol, tyrosol, oleuropein and its derivatives), protect VOO from oxidation and possess beneficial effects on cardiovascular health by protecting blood lipids from oxidative free radicals [4]. In recent years, proteins and peptides have also been described as part of a group of olive oil micronutrients [5]. However, the effects of the composition and the functions that peptides and proteins may have on the quality of VOO and their possible health benefits have been poorly studied.

Food proteins from plant and animal sources have been used to obtain a wide range of peptides with biological activity. Previous research studies and clinical trials in humans have shown a good number of health benefits produced by food-derived peptides,
including antihypertensive [6], anticancer [7–9], hypocholesterolemic [10,11], hypotriglyceridemic [12], antioxidant [13–15], anti-diabetic [16,17], anti-inflammatory [18,19], immunostimulating [20,21], antithrombotic [22,23], antiobesity [24,25], neuromodulatory and opioid [26,27].

High blood pressure is a primary and controllable risk factor of cardiovascular disease that affects approximately 40% of adults [28]. The angiotensin-converting enzyme (ACE) of the renin–angiotensin system plays a key role in regulating blood pressure. Inhibition of ACE is a widely used strategy for the treatment of hypertension [29]. A considerable number of low molecular weight peptides from foods have shown ACE-inhibitory activity. They are mostly produced via enzyme hydrolysis of proteins from animal or vegetable origins [30], although they can also occur naturally [31,32]. A well-known example of ACE-inhibitory peptides with antihypertensive activity are VPP and IPP, derived from milk casein. A recent meta-analysis including 30 randomised controlled clinical trials in which VPP and IPP were administered to human subjects concluded that the supplementation of pre- or hypertensive humans with VPP and IPP for longer than four weeks resulted in a significant reduction in systolic and diastolic blood pressure [33]. Indeed, food-derived peptides may have enormous potential for health and therapy by influencing the metabolic reactions directly involved in risk factors for chronic diseases [34].

In previous work carried out in our laboratory, we showed that unfiltered VOO contains peptides with ACE-inhibitory activity and antihypertensive activity [35]. However, the sequences of the detected low molecular weight peptides were only established preliminarily with the tools available [36]. In this study, we have used the recently available genome database and de novo sequencing assisted database (DB) search to investigate the composition of the endogenous peptides present in VOO, the protein sources from which those peptides originate and their biological activities.

2. Results and Discussion
2.1. Endogenous Peptides Identified by Peaks DB in VOO

In this study, the composition of low molecular weight peptides, as well as their ACE-inhibitory and antioxidant activities, were investigated in a water-soluble extract of unfiltered VOO. Our previous results showed that unfiltered VOO may contain between 0.3 and 1.2 mg of proteins per 100 g of oil [36]. ACE-inhibitory and antihypertensive peptides typically have molecular weights below 3000 Da [37], therefore, we focused the analysis on the low molecular weight fractions of VOO peptides. A widely accepted method for peptide and protein identification is to match MS/MS data to sequenced genomes or by de novo sequencing with software packages, such as PEAKS [38]. Using the available Olea europaea genome database, Peaks DB software identified 19 endogenous peptides in VOO with $-\log_{10} \text{P} > 30$ that were not reported before. Table 1 shows a list of the identified peptide sequences and a selection of peptide parameters, including suggested protein sources (BLASTP) and accession numbers for the proteins containing the peptides. Peptide no. 19 (CPANGFY) with a $-\log_{10} \text{P}$ score of 29.54 was also included in the list due its potential biological activity (peptides reported by Peaks DB with a $-\log_{10} \text{P}$ score $> 25$ are shown in Supplementary Materials Table S1).

The identified peptides possessed between 7 and 23 amino acids and molecular masses ranging from 759 to 2673 Da. Peptide nos. 2, 3, 6 and 10 are related as follows: The amino acid sequences of peptides nos. 2, 6 and 10 are contained within the sequence of peptide no. 3, and the sequences of peptide nos. 2, 6 and 10 overlap. As expected, a high proportion of hydrophobic amino acids were detected in the sequences. Interestingly, the presence of hydrophobic or basic charged amino acids, such as arginine or lysine, was also detected within the last three amino acids of the C-terminal position for peptides no. 1–10, 12–14, 17 and 19. ACE-inhibitory peptides usually contain hydrophobic and/or basic charged amino acids at the C-terminal position [39]. In addition, most antioxidant peptides described in the literature present a high content of histidine and hydrophobic amino acids [40]. Peptide
nos. 7, 14, 17, 18 and 19 possessed cysteine residues, which are often involved in electron transfer reactions with antioxidant potential [41].

### Table 1. Endogenous peptides identified in virgin olive oil using Peaks database (DB) algorithm:

| No. | Sequence                        | −10 lgP | N  | m/z   | Mass          | RT   | ppm    | Area      | Protein Source (BLASTP)                                      | Accession                          |
|-----|---------------------------------|---------|----|-------|---------------|------|--------|-----------|------------------------------------------------------------|-----------------------------------|
| 1   | LDTANEMNQLDLQFR                 | 93.56   | 15 | 904.4365 | 1806.8571     | 34.18 | 8.3    | 1.0 × 10^6 | 11S globulin subunit beta-like                             | OE9A085162P3: OE9A085162P1: OE9A085162P2 |
| 2   | VVLQDTSNNVNQLD                  | 77.73   | 14 | 779.8878 | 1557.7634     | 24.96 | 5.9    | 3.44 × 10^3 | legumin A-like                                             | OE9A032471P1: OE9A042009P1         |
| 3   | VVLQDTSNNVNQLDDIPRRFLA          | 63.26   | 23 | 892.1344 | 2673.3875     | 48.98 | 5.2    | ND        | legumin A-like                                             | OE9A032471P1: OE9A042009P1         |
| 4   | AVVPWQLQPDTPAR                  | 57.79   | 14 | 781.9397 | 1561.8616     | 38.09 | 9.6    | 4.39 × 10^5 | apyrase-like                                               | OE9A017181P2: OE9A017181P1         |
| 5   | IFSGGESSQPR                     | 57.53   | 12 | 611.2961 | 1220.5785     | 22.47 | 6.8    | 1.24 × 10^5 | legumin A-like                                             | OE9A032471P1: OE9A042009P1         |
| 6   | DTSNNVNQLDDIPRR                 | 46.89   | 15 | 586.2892 | 1755.8500     | 26.25 | 5.1    | 1.54 × 10^5 | legumin A-like                                             | OE9A032471P1: OE9A042009P1         |
| 7   | NCSTSISG                        | 39.01   | 9  | 441.2062 | 880.3961      | 35.88 | 9.5    | 3.49 × 10^5 | hypothetical predicted protein                            | OE9A087501P1:                     |
| 8   | VHVFRFDQNLDDQF                 | 34.71   | 17 | 671.3506 | 2011.0275     | 48.03 | 8.8    | 1.53 × 10^4 | apyrase-like                                               | OE9A017181P2: OE9A017181P1         |
| 9   | LLLLAGCM(+15.99)                | 34.51   | 8  | 397.1985 | 792.3874      | 33.76 | 1.4    | 1.24 × 10^7 | zinc transporter 5-like                                     | OE9A117792P1:                     |
| 10  | QDTSNNVNQLDDIPRR               | 33.36   | 16 | 628.9771 | 1883.9086     | 26.36 | 8.0    | 2.06 × 10^6 | legumin A-like                                             | OE9A032471P1: OE9A042009P1         |
| 11  | FSASTEGR                       | 32.74   | 8  | 393.1665 | 784.3239      | 25.27 | 0.5    | 9.63 × 10^5 | probable L-type lectin domain containing receptor kinase 5.7 | OE9A013295P1: OE9A013295P2: OE9A082197P1 |
| 12  | INTISGR                         | 31.90   | 7  | 380.7197 | 759.4239      | 20.53 | 8.6    | 1.38 × 10^5 | legumin A-like                                             | OE9A032471P1: OE9A042009P1         |
| 13  | LDGNSSAR                        | 31.66   | 8  | 410.1964 | 818.3882      | 18.63 | −4.9   | 1.41 × 10^5 | late blight resistance protein homolog R1A-10             | OE9A106456P1:                     |
| 14  | VCGEAFGKA                      | 31.36   | 9  | 441.2060 | 880.4113      | 33.38 | −8.2   | 4.18 × 10^6 | translation initiation factor IF-2, chloroplastic          | OE9A058866P1:                     |
| 15  | KGGGGGSGSSAAGGGS                | 31.14   | 15 | 525.2275 | 1048.4534     | 35.95 | −4.9   | 4.01 × 10^5 | mitogen-activated kinase 9-like, partial                   | OE9A057915P1:                     |
| 16  | SCIPGHNEQ                      | 30.94   | 8  | 413.1722 | 824.3413      | 30.38 | −6.5   | ND        | hypothetical predicted protein                             | OE9A054657P1: OE9A104108P1:         |
| 17  | LGGGGGSGGGAAC                   | 30.30   | 12 | 447.1878 | 892.3708      | 20.67 | −3.4   | 4.31 × 10^5 | VASP homolog (vasodilator-stimulated phosphoprotein)        | OE9A026632P1:                     |
| 18  | NALLCSNS                       | 30.09   | 8  | 411.1950 | 820.3749      | 27.63 | 8.1    | 2.25 × 10^5 | transcription factor bHLH143-like                        | OE9A100476P1:                     |
| 19  | CPANGFY                        | 29.54   | 7   | 386.1598 | 770.3057      | 26.19 | 6.7    | ND        | basic endochitinase-like                                   | OE9A087887P1:                     |

### 2.2. Olive Proteins Detected as Sources of VOO Peptides

A total of 20 proteins from 13 protein groups were reported as sources of the 19 peptide sequences identified by Peaks DB (Table 2). The protein coverage and fragmentation spectra of the 19 supporting peptides are shown in Supplementary Materials Table S2. The *Olea europaea* database used in these analyses was unannotated, so the accession numbers for the proteins containing the peptides were obtained by Peaks DB, but potential
protein identification was not provided. BLAST searches against the non-redundant protein sequences' database at NCBI [42] were carried out in order to identify the protein sources of the peptides detected in VOO.

**Table 2.** Proteins identified as sources of endogenous peptides detected in virgin olive oil: protein \(-10 \lg P\) score, sum of \(-10 \lg P\) scores of a protein’s supporting peptides; peptides, number of high-confidence supporting peptides; cover (%), percentage of the protein sequence covered by supporting peptides; area, protein relative abundance; protein identification, definitions of best-matched proteins identified by BLAST-P search; E-value (score), number of expected hits of similar quality that could be found randomly; protein description, access to protein report.

| Protein Accession | \(-10 \lg P\) | Peptides | Cover (%) | Average Mass (Da) | Area | Protein Identification (BLASTP) | E-Value | % Identity | Protein Description |
|-------------------|--------------|----------|-----------|-------------------|------|-------------------------------|---------|------------|---------------------|
| OE9A02471P1       | 155.75       | 6        | 9         | 51,572            | 2.82 \times 10^6 | legumin A-like | 0.0      | 100        | CAA3011204.1        |
| OE9A02009P1       | 155.75       | 6        | 9         | 51,725            | 2.82 \times 10^6 | legumin A-like | 0.0      | 100        | ID: CAA301904.1     |
| OE9A085162P3      | 93.56        | 1        | 4         | 40,777            | 1.08 \times 10^6 | 11S globulin subunit beta-like | 0.0      | 100        | XP_022872671.1      |
| OE9A085162P2      | 93.56        | 1        | 4         | 44,093            | 1.08 \times 10^6 | 11S globulin subunit beta-like | 0.0      | 100        | CAA2975576.1        |
| OE9A085162P1      | 93.56        | 1        | 4         | 55,757            | 1.08 \times 10^6 | 11S globulin subunit beta-like | 0.0      | 100        | XP_022872671.1      |
| OE9A085162P1      | 93.56        | 1        | 4         | 44,093            | 1.08 \times 10^6 | 11S globulin subunit beta-like | 0.0      | 100        | CAA2975576.1        |
| OE9A001718P2      | 75.15        | 2        | 7         | 47,253            | 4.54 \times 10^5  | apyrase-like | 0.0      | 100        | CAA3020286.1        |
| OE9A001718P1      | 75.15        | 2        | 7         | 49,955            | 4.54 \times 10^5  | apyrase-like | 0.0      | 100        | CAA3020285.1        |
| OE9A057915P1      | 43.19        | 1        | 7         | 21,805            | 4.01 \times 10^6  | mitogen-activated kinase 9-like | 6 \times 10^{-86} | 100 | CAA3032954.1 |
| OE9A117792P1      | 43.16        | 1        | 2         | 38,475            | 6.11 \times 10^6  | zinc transporter 5-like | 0.0      | 100        | CAA3032762.1        |
| OE9A087501P1      | 39.01        | 1        | 4         | 27,647            | 3.49 \times 10^5  | hypothetical predicted protein | 1 \times 10^{-110} | 100 | CAA2984267.1 |
| OE9A013295P1      | 32.74        | 1        | 1         | 72,709            | 9.63 \times 10^5  | probable L-type lectin domain containing receptor kinase S.7 | 0.0      | 100        | CAA2995736.1        |
| OE9A04203P1       | 32.74        | 1        | 1         | 75,341            | 9.63 \times 10^5  | probable L-type lectin domain containing receptor kinase S.7 | 0.0      | 100        | XP_022879160.1      |
| OE9A062197P1      | 32.74        | 1        | 1         | 75,780            | 9.63 \times 10^5  | probable L-type lectin domain containing receptor kinase S.7 | 0.0      | 100        | CAA2978283.1        |
| OE9A106456P1      | 31.66        | 1        | 1         | 86,941            | 7.40 \times 10^4  | late blight resistance protein homolog R1A-10 | 0.0      | 100        | CAA2992924.1        |
| OE9A05886P1       | 31.36        | 1        | 1         | 108,486           | 4.18 \times 10^5  | translation initiation factor IF-2, chloroplastic | 0.0      | 100        | CAA3007316.1        |
| OE9A054657P1      | 30.94        | 1        | 3         | 30,439            | 0                  | hypothetical predicted protein | 4 \times 10^{-128} | 100 | CAA3010733.1 |
| OE9A104108P1      | 30.94        | 1        | 2         | 41,131            | 0                  | hypothetical predicted protein | 2 \times 10^{-112} | 100 | CAA2977756.1 |
| OE9A026632P1      | 30.3         | 1        | 4         | 30,682            | 4.31 \times 10^5  | VASP homolog (vasodilator-stimulated phosphoprotein) | 2 \times 10^{-126} | 100 | CAA2968008.1 |
| OE9A100476P1      | 30.09        | 1        | 2         | 38,275            | 2.25 \times 10^5  | hypothetical predicted protein (transcription factor bHLH143-like) | 0.0      | 100        | CAA298309.1         |
| OE9A087887P1      | 29.54        | 1        | 3         | 28,540            | 0                  | basic endochitinase-like | 0.0      | 100        | CAA2941635.1        |

The sequence of peptide no. 1 was identified as part of the 11S globulin subunit beta, a seed storage protein that has been described in the protein bodies of mature olive seeds [43]. Peptide nos. 2, 3, 5, 6, 10 and 12 were identified as part of legumin A-like protein, which is another kind of major globulin-type seed storage protein. In agreement with this, a recent study investigated the protein composition of VOO via (1-dimension) polyacrylamide gel electrophoresis of extracted proteins and further LC-MS analysis of the sliced protein bands obtained in the gels. The authors identified seed storage proteins of globulin-type
as the most abundant proteins in VOO, including several 11S globulins, also known as legumins [44]. The presence of several peptide sequences derived from legumin-A and 11S globulin indicate that legumins are an important source of peptides in VOO. Legumin-A proteins, found in the seeds of many leguminous and non-leguminous plants, are also a source of sulphur-containing amino acids [45]. The sequences of peptide nos. 4 and 8 are associated with apyrase-like proteins, which catalyse ATP hydrolysis in cells. Peptide no. 9 is derived from a zinc transporter 5-like protein, which presents high homology with other plant zinc transporters. Peptide no. 11’s sequence is derived from L-type lectin receptor kinase S7, a plant kinase described to be involved in defence response and pollen formation [46]. Peptide no. 13 originates from protein homolog R1A-10, an ATP-binding protein that has been described to trigger a defence system against late blight produced by the pathogen Phytophthora infestans [47]. Peptide no. 14 is obtained from translation initiation factor IF-2, a chloroplastic GTP- and mRNA-binding protein involved in protein synthesis [48]. The sequence of peptide no. 15 originates from a mitogen-activated kinase 9, which is an ATP-binding protein with kinase activity involved in plant intracellular signal transduction [49]. Peptide no. 17 contains 50% glycine and is produced from a homologue of vasodilator-stimulated phosphoprotein (VASP), which associates with actin proteins and regulates chemotaxis [50]. The sequence of peptide no. 18 derives from a hypothetically predicted protein with high homology to transcription factor bHLH143, a member of the basic/helix–loop–helix (bHLH) family of transcription factors, which bind to specific DNA sites and regulate many biological processes [51]. Peptide no. 19 seems to originate from a basic endochitinase-like protein. Arabidopsis endochitinases are involved in chitin degradation and protect plants from pathogen attack [52]. The sequences of peptides nos. 7 and 16 are part of hypothetically predicted proteins detected in the olive database with unknown functions as of yet. All of the proteins above are presumably present in the olive oil seed, mesocarp or epidermis and are subjected to degradation, either previously or during extraction of VOO, or perhaps originate from VOO proteins.

The identification of olive peptides and proteins is a difficult task. The proteome of Olea europaea is, with a few exceptions, mostly uncharacterised, and the genomic and transcriptomic databases available contain computationally analysed records. As of December 2021, there are only 112 reviewed sequences in Swiss-Prot and 12,246 unreviewed TrEMBL sequences, i.e., translations of all coding sequences present in the EMBL/GenBank/DDBJ Nucleotide Sequence Databases as well as protein sequences extracted from the literature or submitted to UniProtKB/Swiss-Prot, that await revision. This is probably why the peptides that we found in olive oil have not been reported before and why only a few proteins have been identified as possible sources of peptides.

2.3. Endogenous Peptides Identified by de Novo Sequencing in VOO

Eight novel peptides (not present in the olive database), with ALC % above 90, were confidently identified by Peaks de novo sequencing algorithm (Table 3). The peptides detected were short (six or seven amino acids) and rich in hydrophobic amino acids (>50%). The majority contained one or two histidines and/or cysteines in their sequences. The fragmentation spectra, total ion chromatogram and retention times of the de novo peptides reported in Table 3 are shown in Supplementary Materials Figure S1. The novel peptides identified by de novo sequencing with ALC% > 80 are shown in Supplementary Materials Table S3.
Table 3. Endogenous peptides identified in virgin olive oil by de novo sequencing: ALC, average local confidence; N, number of amino acids; m/z, precursor mass-to-charge ratio; mass, peptide mass in Da; RT, retention time; area, peptide abundance shown as area under the curve of the detected peptide; ppm, precursor mass error; local confidence, local confidence score for each amino acid of the peptide identified by de novo sequencing. Oxidised methionine is indicated by a pair of parentheses enclosing the modification mass (+15.99). ND, not detected.

| No. | Peptide     | ALC (%) | N  | m/z       | Mass     | RT     | Area         | ppm     | Local Confidence (%) |
|-----|-------------|---------|----|-----------|----------|--------|--------------|---------|----------------------|
| 1   | de novo CCYSVY | 95      | 6  | 369.1365  | 736.256  | 24.36  | 5.77 × 10^{-5} | 3.2     | 92 97 99 93 92 98    |
| 2   | de novo DCHYFL | 94      | 6  | 399.1715  | 796.3214 | 25.13  | 6.41 × 10^{-5} | 8.9     | 92 98 98 98 90 93    |
| 3   | de novo LYPFAH | 94      | 6  | 374.1952  | 746.3751 | 19.07  | 3.59 × 10^{-5} | 1       | 99 99 99 85 89 93    |
| 4   | de novo SVSKPGW | 10       | 7  | 380.7006  | 759.3915 | 14.03  | 1.85 × 10^{-5} | 6.5     | 93 97 99 99 89 78 93 |
| 5   | de novo LHTVVH | 91      | 6  | 353.2084  | 704.397  | 26.06  | 8.67 × 10^{-5} | 7.6     | 99 93 93 92 85 87    |
| 6   | de novo NKLCEEH | 91      | 7  | 423.6815  | 845.3524 | 29.15  | ND           | 4.7     | 84 95 98 94 86 94 89 |
| 7   | de novo DHHEEL | 91      | 6  | 390.1661  | 778.3246 | 36.35  | 7.71 × 10^{-5} | 8.9     | 89 91 97 91 92 85    |
| 8   | de novo LPCAAHR | 90      | 7  | 384.2062  | 766.3908 | 19.09  | 2.70 × 10^{-5} | 9.2     | 98 79 79 89 97 96 95 |

2.4. Predicted Activities of VOO Endogenous Peptides

The predicted biological activities of the VOO endogenous peptides detected by Peaks DB and Peaks de novo sequencing algorithm are reported in Tables 4 and 5, respectively. We used the BIOPEP database of bioactive peptides to investigate their biological activity because it uses previously published records to calculate a peptide’s theoretical activity, as well as the number of active motifs within each peptide sequence.

Table 4. Predicted activity of VOO endogenous peptides identified by Peaks DB using BIOPEP-UWM database of bioactive peptides: ACE, angiotensin-converting enzyme; DPP III, dipeptidyl peptidase-III; DPP IV, dipeptidyl peptidase-IV; A, ratio of number of sequences with predicted activity to number of amino acids; B, potential biological activity of the peptide (µM⁻¹) theoretically calculated from previous bioactive referenced data. A and B values obtained from BIOPEP-UWM database.

| No. | Peptide Sequence | Predicted Activity       | No. of Sequences with Activity | A                | B               |
|-----|------------------|--------------------------|--------------------------------|-----------------|-----------------|
| 1   | LDTANEMNQLDLQFR  | ACE inhibitor             | 3                              | 0.2000          | 7.24 × 10^{-5}  |
|     |                  | DPP IV inhibitor          | 7                              | 0.4667          |                 |
|     |                  | DPP III inhibitor         | 1                              | 0.0667          |                 |
|     |                  | Renin inhibitor           | 1                              | 0.0667          |                 |
| 2   | VVLQDTSNIVNQLD   | ACE inhibitor             | 2                              | 0.1429          |                 |
|     |                  | Glucose uptake stimulation| 1                              | 0.0714          |                 |
|     |                  | DPP IV inhibitor          | 9                              | 0.6429          | 9.65 × 10^{-4}  |
| 3   | VVLQDTSNNVQLDDIPRFLA | ACE inhibitor          | 9                              | 0.3913          | 1.36 × 10^{-2}  |
|     |                  | Activator of ubiquitin-mediated | 1                              | 0.0435          |                 |
|     |                  | proteolysis               |sw     |                 |                 |
|     |                  | DPP IV inhibitor          | 10                             | 0.2174          |                 |
|     |                  | DPP III inhibitor         | 5                              | 0.6087          | 8.62 × 10^{-4}  |
|     |                  | Stimulation               | 1                              | 0.0435          |                 |
| 4   | AVVPPLQLPDPRAR   | ACE inhibitor             | 10                             | 0.7143          | 5.69 × 10^{-2}  |
|     |                  | DPP IV inhibitor          | 10                             | 0.7143          | 1.80 × 10^{-3}  |
| No. | Peptide Sequence       | Predicted Activity                          | No. of Sequences with Activity | A     | B           |
|-----|-----------------------|---------------------------------------------|---------------------------------|-------|-------------|
| 5   | IFSGGESSGQPR          | ACE inhibitor                                | 9                               | 0.7500 | $4.63 \times 10^{-2}$ |
|     |                       | Antioxidant                                  | 1                               | 0.0833 |             |
|     |                       | DPP III inhibitor                            | 2                               | 0.1667 |             |
|     |                       | DPP IV inhibitor                             | 4                               | 0.3333 |             |
|     |                       | Neuropeptide                                 | 1                               | 0.0833 |             |
| 6   | DTSNNVNQQLDIPRR       | ACE inhibitor                                | 3                               | 0.2000 | $1.70 \times 10^{-2}$ |
|     |                       | DPP IV inhibitor                             | 8                               | 0.1333 |             |
|     |                       | DPP III inhibitor                            | 2                               | 0.5333 | $1.62 \times 10^{-4}$ |
| 7   | NCSTSIISG             | ACE inhibitor                                | 2                               | 0.2222 | $2.75 \times 10^{-2}$ |
|     |                       | DPP IV inhibitor                             | 3                               | 0.3333 |             |
|     |                       | Glucose uptake stimulation                   | 1                               | 0.1111 |             |
| 8   | VHVFREDQNDLPIGN       | ACE inhibitor                                | 5                               | 0.2941 | $8.20 \times 10^{-3}$ |
|     |                       | Glucose uptake stimulation                   | 1                               | 0.0588 |             |
|     |                       | DPP IV inhibitor                             | 11                              | 0.6471 | $2.48 \times 10^{-5}$ |
|     |                       | DPP III inhibitor                            | 2                               | 0.1176 |             |
| 9   | LLLGAGCM(+15.99)      | ACE inhibitor                                | 3                               | 0.3750 | $1.26 \times 10^{-4}$ |
|     |                       | Glucose uptake stimulation                   | 2                               | 0.3750 |             |
|     |                       | Stimulation of vasoactive substance release  | 1                               | 0.3750 |             |
|     |                       | DPP IV inhibitor                             | 3                               | 0.5000 |             |
| 10  | QDTSNNVNQQLDIPRR      | ACE inhibitor                                | 3                               | 0.1875 | $1.59 \times 10^{-2}$ |
|     |                       | DPP IV inhibitor                             | 9                               | 0.5625 | $1.52 \times 10^{-4}$ |
|     |                       | DPP III inhibitor                            | 2                               | 0.1250 |             |
| 11  | FSASTEGS              | ACE inhibitor                                | 4                               | 0.5000 | $3.11 \times 10^{-2}$ |
|     |                       | DPP IV inhibitor                             | 3                               | 0.3750 |             |
| 12  | INTISGR               | ACE inhibitor                                | 2                               | 0.2857 | $6.14 \times 10^{-5}$ |
|     |                       | DPP IV inhibitor                             | 3                               | 0.4286 |             |
| 13  | LDGNSSAR              | ACE inhibitor                                | 2                               | 0.2500 | $1.14 \times 10^{-2}$ |
| 14  | VCGEAFGKA             | ACE inhibitor                                | 7                               | 0.7778 | $4.80 \times 10^{-3}$ |
|     |                       | Alpha-glucosidase inhibitor                  | 1                               | 0.1111 | $6.53 \times 10^{-6}$ |
|     |                       | DPP IV inhibitor                             | 3                               | 0.3333 | $1.78 \times 10^{-5}$ |
|     |                       | DPP III inhibitor                            | 2                               | 0.2222 |             |
| 15  | KGGGGGSAGGGGS         | ACE inhibitor                                | 13                              | 0.8667 | $1.72 \times 10^{-4}$ |
|     |                       | DPP IV inhibitor                             | 9                               | 0.6000 |             |
| 16  | SGIPGNHEQ             | ACE inhibitor                                | 4                               | 0.5000 | $2.10 \times 10^{-3}$ |
|     |                       | Antiinmensive                                | 2                               | 0.2500 |             |
|     |                       | Antithrombotic                               | 2                               | 0.2500 |             |
|     |                       | Regulation of stomach mucosal activity       | 2                               | 0.2500 |             |
|     |                       | DPP IV inhibitor                             | 4                               | 0.5000 | $1.80 \times 10^{-3}$ |
| 17  | LGGGGSSGAAC           | ACE inhibitor                                | 9                               | 0.7500 | $2.63 \times 10^{-4}$ |
|     |                       | Antioxidant                                  | 1                               | 0.0833 |             |
|     |                       | DPP IV inhibitor                             | 6                               | 0.5000 | $8.87 \times 10^{-6}$ |
| 18  | NALLCSNS              | Glucose uptake stimulation                   | 1                               | 0.1250 | $1.42 \times 10^{-6}$ |
|     |                       | DPP IV inhibitor                             | 3                               | 0.3750 |             |
| 19  | CPANGFY               | ACE inhibitor                                | 3                               | 0.4286 | $5.90 \times 10^{-3}$ |
|     |                       | DPP IV inhibitor                             | 3                               | 0.4286 |             |
|     |                       | DPP III inhibitor                            | 1                               | 0.1429 |             |
Table 5. Predicted activity of endogenous peptides identified in virgin olive oil by de novo sequencing using BIOPEP-UWM database of bioactive peptides: ACE, angiotensin converting enzyme; DPP III, dipeptidyl peptidase-III; DPP IV, dipeptidyl peptidase-IV; A, ratio of number of sequences with predicted activity to number of amino acids; B, potential biological activity of the peptide (µM⁻¹) theoretically calculated from previous bioactive referenced data. A and B values obtained from BIOPEP-UWM database.

| No. | Peptide | ALC (%) | Predicted Activity                     | No. Seq. with Activity | A       | B               |
|-----|---------|---------|--------------------------------------|------------------------|---------|-----------------|
| 1   | de novo | CCYSVY  | 95                                   | ACE inhibitor          | 2       | 0.3333          |
|     |         |         |                                      | Anti-oxidant           | 1       | 0.1667          |
|     |         |         |                                      | DPP III inhibitor      | 3       | 0.1667          |
|     |         |         |                                      | DPP IV inhibitor       | 1       | 0.5000          |
| 2   | de novo | DCHYFL  | 94                                   | ACE inhibitor          | 1       | 0.1667          |
|     |         |         |                                      | Anti-inflammatory      | 1       | 0.1667          |
|     |         |         |                                      | DPP III inhibitor      | 3       | 0.3333          |
|     |         |         |                                      | DPP IV inhibitor       | 2       | 0.5000          |
| 3   | de novo | LYPFAH  | 94                                   | ACE inhibitor          | 4       | 0.6667          |
|     |         |         |                                      | Alpha-glucosidase      | 1       | 0.1667          |
|     |         |         |                                      | inhibitor              | 2       | 0.3333          |
|     |         |         |                                      | DPP III inhibitor      | 2       | 0.3333          |
|     |         |         |                                      | DPP IV inhibitor       | 4       | 0.6667          |
|     |         |         |                                      | Opioid                 | 1       | 0.1667          |
|     |         |         |                                      | Renin inhibitor        | 1       | 0.1667          |
| 4   | de novo | SVSKPGW | 92                                   | ACE inhibitor          | 3       | 0.4286          |
|     |         |         |                                      | Anti-iamnestic         | 1       | 0.1429          |
|     |         |         |                                      | Anti-oxidant           | 1       | 0.1429          |
|     |         |         |                                      | Antithrombotic         | 1       | 0.1429          |
|     |         |         |                                      | Regulation of stomach  | 1       | 0.1429          |
|     |         |         |                                      | activity               | 6       | 0.8571          |
| 5   | de novo | LHTVVH  | 91                                   | Anti-oxidant           | 2       | 0.3333          |
|     |         |         |                                      | DPP IV inhibitor       | 5       | 0.8333          |
| 6   | de novo | NKLCCEH | 91                                   | ACE inhibitor          | 3       | 0.4286          |
|     |         |         |                                      | DPP IV inhibitor       | 1       | 0.1429          |
| 7   | de novo | DHHEEL  | 91                                   | Anti-oxidative         | 3       | 0.5000          |
|     |         |         |                                      | Stimulation of vasoact| 1       | 0.1667          |
|     |         |         |                                      | ive substance release  | 2       | 0.3333          |
| 8   | de novo | LPCAAHR | 90                                   | ACE inhibitor          | 2       | 0.2857          |
|     |         |         |                                      | Anti-oxidant           | 1       | 0.1429          |
|     |         |         |                                      | DPP IV inhibitor       | 4       | 0.5714          |

According to BIOPEP, 24 peptides possessed ACE-inhibitory activity, and 26 peptides showed dipeptidyl peptidase (DPP)-III- and /or IV-inhibitory activity. As mentioned before, ACE inhibition is a target for the treatment of hypertension. DPP-III plays a role in blood pressure regulation, as well, by modulating angiotensin I and II [53]. Human DPP-IV is involved in blood glucose regulation, and its inhibition is used as a target for antidiabetic drugs [54]. Antioxidative activity was reported for eight peptide sequences. Other biological activities detected in the peptides were glucose uptake stimulation (see Table 4 nos. 2, 7, 8, 9), renin inhibitors, anti-inflammatory, antithrombotic, anti-iamnestic, opioid, stimulation of vasoactive substance release, alpha-glucosidase inhibitor, regulation of stomach mucosal activity and activator of ubiquitin-mediated proteolysis. New sources of ACE inhibitors and antioxidants are of interest for the food and pharmaceutical industries, so we focused on the study of those activities. Potential antioxidant activities of peptides are particularly interesting due to the implications they may have for the quality and stability of VOO.
Other peptide activities, such as the inhibitors of DPP-III and IV, are also of great interest and could be the subject of further studies.

The capacity of peptides to produce systemic effects, such as inhibition of ACE, is conditioned by their bioavailability to reach blood and organs. Proteins and peptides are metabolised to single amino acids, but peptides containing two, three or more amino acids can be absorbed directly into the blood. This is determined by the proteolytic action of digestive enzymes. This aspect was investigated in our detected peptide sequences. The in silico-simulated proteolytic activity of pepsin, trypsin and chymotrypsin on the peptides identified by Peaks DB and by de novo sequencing produced different molecular species (Table 6). Digestive enzymes originated a number of di- and tri-peptides (QF, IF, RF, GF, VVL and SVY) with previously reported ACE- (or renin-) inhibitory activity [55], suggesting that some peptides would still be able to produce an inhibition of ACE after digestion in the gut.

### Table 6. Molecular species (predicted) produced by the proteolytic activity of main digestive enzymes acting on peptides identified by Peaks DB and by PEAKS de novo sequencing: ACE, angiotensin converting enzyme; DPP, dipeptidyl peptidase. Peptide fragments with previously reported bioactivity are shown in red.

| No. | Peptide Sequence | Pepsin | Trypsin | Chymotrypsin |
|-----|------------------|--------|---------|--------------|
| 1   | LDTANEMNQLDLQFR  | L-DTANEMNQL-DL-QF-R | L-DTAN-EM-N-QL-DL-QF-R | L-DTAN-EM-N-QL-DL-QF-R |
|     |                  | QF: renin inhibitor, QF, DPP IV, inhibitor | QF, renin inhibitor, QF, QL: DPP IV, inhibitor |
| 2   | VVLQDTSNNVNQLD   | VVL-QDTSNNVNQL-D | VVL-QDTSNNVNQL-D | VVL-QDTSN-N-VN-QL-D |
|     |                  | VVL: ACE inhibitor | VVL: ACE inhibitor | VVL: ACE inhibitor |
|     |                  | QL, VN: DPP IV, inhibitor |
| 3   | VVLQDTSNNVNQLDIPRFFL Ala | VVL-QDTSNNVNQL-DDIPRRF-F-L-A | VVL-QDTSN-N-VN-QL-DDIPRRF-F-L-A | VVL: ACE inhibitor |
|     |                  | VVL: ACE inhibitor |
|     |                  | QL, VN: DPP IV, inhibitor |
| 4   | AVVPIWLQPDPTRAR  | IF-SGGESSGQPR | IF-SGGESSGQPR | IF-SGGESSGQPR |
|     |                  | IF: ACE inhibitor |
| 5   | DTSNNVNQLDDIPR   | DTSN-N-VN-QL-DDIPR | DTSN-N-VN-QL-DDIPR | DTSN-N-VN-QL-DDIPR |
|     |                  | QL, VN: DPP IV, inhibitor |
| 6   | NCSTSISSG       | IN: DPP-IV inhibitor |
|     |                  | IN: DPP-IV inhibitor |
| 7   | LDGNSSAR         | RF: DPP-III inhibitor |
| 8   | VHVFRFDQNDLPIGN | VHF-RF-DQNQDL-L-PIGN | VHF-RF-DQNQDL-L-PIGN | VHF-RF-DQNQDL-L-PIGN |
|     |                  | RF: ACE inhibitor | RF: ACE inhibitor | RF: ACE inhibitor |
|     |                  | RF: DPP-III inhibitor |
| 9   | QDSNINQNLDDIPR  | QDTSN-N-VN-QL-DDIPR | QDTSN-N-VN-QL-DDIPR | QDTSN-N-VN-QL-DDIPR |
|     |                  | QL, VN: DPP IV, inhibitor |
| 10  | FSASTEGS         | F-SASTEGS |
| 11  | INTISGR          | IN: TISGR |
|     |                  | IN: DPP-IV inhibitor |
| 12  | LDGNSSAR         | RF: DPP-III inhibitor |
| 13  | VCGEAFGKA        |
Table 6. Cont.

| No.  | Peptide Sequence | Pepsin        | Trypsin        | Chymotrypsin          |
|------|-----------------|---------------|---------------|-----------------------|
| 15   | KGGGGGSAGGGGS   |               |               |                       |
| 16   | SGPNHEQ         |               |               |                       |
| 17   | LGGGSSGGAAC     |               |               |                       |
| 18   | NALLCSNS        |               | AL: DPP-IV inhibitor |                       |
|      |                 |               | CPAN-GF-Y     |                       |
|      |                 |               | GF: ACE inhibitor |                       |
|      |                 |               | GF: DPP IV inhibitor |                       |
|      |                 |               | GF: DPP III inhibitor |                       |
| 19   | CPANGFY         | AL: DPP-IV inhibitor |               |                       |
|      |                 | CPAN-GF-Y     |               |                       |
|      |                 | GF: ACE inhibitor |               |                       |
|      |                 | GF: DPP IV inhibitor |               |                       |
|      |                 | GF: DPP III inhibitor |               |                       |
| 1 de novo | CCYSVY           |               | CCY-SVY       |                       |
| 2 de novo | DCHYFL          |               | SVY: ACE inhibitor |                       |
| 3 de novo | LYPFAH          |               | L-YPF-AH      |                       |
| 4 de novo | SVSKPGW         |               |               |                       |
| 5 de novo | LHTVVH          |               |               |                       |
| 6 de novo | NKLCCEH         |               |               |                       |
| 7 de novo | DHHEEL          |               |               |                       |
| 8 de novo | LPCAAHR         |               |               |                       |

2.5. ACE-Inhibitory and Antioxidant Activity of Synthetic Peptides

We investigated the potential ACE-inhibitory and antioxidant activities by using synthetic peptides. Due to the high percentage of hydrophobic and neutral amino acids (>85%), water solubility was problematic for many peptide sequences, so they had to be excluded from the analysis. Out of the 27 sequences identified, seven Peaks DB peptides (nos. 1, 2, 5, 10, 14, 18 and 19), and two de novo sequencing peptides (nos. 1 and 2) were selected for in vitro studies using the selection criteria described in Section 2.5. We included peptide sequences containing one or more cysteine amino acids because thiol groups are very susceptible to oxidations, hence their potential antioxidant activity. This is the case of glutathione, a cysteine-containing tripeptide which is a principal cellular antioxidant.

Peaks DB sequences VGGEAFKA (no. 14), NALLCSNS (no. 18) CPANGFY (no. 19) and de novo identified sequences CCYSVY (no. 1) and DCHYFL (no. 2) showed strong ACE-inhibitory and antioxidant activities (Table 7). The C-terminal dipeptide KA present in sequence no. 14 has been reported to inhibit ACE with an IC<sub>50</sub> value of 31.5 µM [56], which may explain the similar activity values detected by us. The ACE-inhibitory activity of NALLCSNS was remarkable and unexpected because no previous records of ACE-inhibitor peptides or di- or tripeptide fragments contained in the sequence were found that could explain the activity. Regarding CPANGFY (no. 19), the ACE-inhibitory values reported for C-terminal dipeptide FY (IC<sub>50</sub> range 1.65–42.6 µM) [55,57] are in agreement with our results. Dipeptide GF, originated by the chymotrypsin digestion of the sequence (Table 6), also possesses ACE-inhibitory activity [58]. In addition, both FY and GF have been confirmed in vivo for antihypertensive activity. Dipeptide VY and tripeptide SVY
present at the C-terminal end of de novo peptide no. 1 have been shown to possess strong ACE-inhibitory activities of the same order of magnitude of the well-known ACE-inhibitory (and antihypertensive) peptides IPP (IC$_{50}$ 5 µM) and VPP (IC$_{50}$ 9 µM) described in dairy [33,59]. Indeed, the IC$_{50}$ values reported for VY and SVY are 7.1 µM and 8.1 µM, respectively [55,60]. The IC$_{50}$ values measured by us for CYSVY are in agreement with the above results. Tripeptide SVY also seems to be produced by the proteolytic activity of chymotrypsin (Table 6). Regarding de novo peptide no. 2, C-terminal dipeptide FL has also been shown to produce inhibition of ACE with an IC$_{50}$ value of 15.8 µM [55].

Table 7. ACE-inhibitory activity and ABTS radical antioxidant capacity of a selection of synthetic peptides detected in virgin olive oil. Peptide nos. 1, 2, 5, 10, 14, 18 and 19 were identified by Peaks DB algorithm; peptide nos.1 de novo and 2 de novo were identified by Peaks de novo sequencing algorithm: ACEi activity, angiotensin-converting enzyme inhibitory activity; IC$_{50}$ (µM), peptide concentration necessary to inhibit 50% of ACE activity, expressed in µM. Antioxidant activity is referred to Trolox and expressed as TEAC (Trolox Equivalent Antioxidant Capacity). Data are means ± SD of three different experiments. ND, not detected.

| No. | Peptide Sequence | ACEi Activity IC$_{50}$ (µM) ± SD | TEAC ± SD |
|-----|------------------|-----------------------------------|----------|
| 1   | LDTHANEMNQLDLQFR | ND                                | ND       |
| 2   | VVLQDTSNNVNQLD  | ND                                | ND       |
| 5   | IFSGGESSGQPR     | ND                                | ND       |
| 10  | QDTSNNVNQLDDIPRR| ND                                | ND       |
| 14  | VCGEAFGKA        | 57.2 ± 4.31                       | 0.79 ± 0.02 |
| 18  | NALLCSNS         | 0.98 ± 0.04                       | 0.95 ± 0.03 |
| 19  | CPANGFY          | 3.76 ± 0.39                       | 1.53 ± 0.14 |
| 1 de novo | CCYSVY   | 25.6 ± 0.41                       | 3.20 ± 0.19 |
| 2 de novo | DCHYFL   | 41.5 ± 2.09                       | 2.36 ± 0.02 |

Antioxidant effects of plants are known mostly because of the radical scavenging properties of their polyphenolic, carotenoid and antioxidant vitamin contents. However, recent studies have shown that many proteins and peptides from plants possess strong antioxidant activity. This activity has been evaluated by using in vitro methods, such as the ABTS radical scavenging capacity, before being assessed in cellular systems or in vivo animal models [61–63]. Mechanisms proposed for the antioxidant activity of peptides include free radical scavenging and chelation of transition metals [64]; induction of antioxidant enzymes, such as catalase or superoxide dismutase [65]; induction of antioxidant molecules (e.g., glutathione), which protect cells from damage by reactive oxygen species [66,67]; and inhibition of oxidative enzymes, such as lipoxygenase, which catalyses oxidation of unsaturated fatty acids [14]. Antioxidant activity of peptides has been attributed to certain sequences of amino acids containing cysteine, methionine, lysine, histidine, tryptophan and tyrosine [68,69]. Hydrophobic peptides may also present advantages regarding their antioxidant activity because of their easier access to hydrophobic molecules, such as fatty acids [13].

VOO peptides VCGEAFGKA (no. 14), NALLCSNS (no. 18) and CPANGFY (no. 19), as well as de novo CCYSVY (no. 1) and DCHYFL (no. 2), all contained hydrophobic amino acids in the C-terminal position and also one or two antioxidant cysteines, which could explain their activity. The antioxidant activity reported for glutathione is 0.9 TEAC [70], so the antioxidant activity measured for the five peptides (0.8–3.2 TEAC) is quite strong. The presence of antioxidant peptides in VOO may positively affect the quality of the oil. Oxygen and light are inducers of lipid hydro peroxide radicals, which lead to oxidation of olive oil fatty acids. Polyphenols and alpha-tocopherols are able to quench oxygen free
radicals and lipid peroxides, therefore protecting VOO from oxidation. The content of both antioxidant polyphenols and alpha-tocopherols are indicators of VOO quality [71]. Antioxidant peptides could also play a significant role in VOO quality. In addition, antioxidant peptides could act in cooperation with antioxidant polyphenols. For example, the antioxidant activity of peptides containing cysteine, once oxidised, may be recycled back to their reduced forms by polyphenols. In this regard, we have recently reported the presence of significant amounts of reduced glutathione (>5 mg/100 g) in mature olives, which may be recycled by olive polyphenols when glutathione is oxidised [72]. Although we could not detect glutathione in VOO (not shown), antioxidant peptides, such as the ones shown above, could have a similar antioxidant role to glutathione in olives. One limitation of this study is a lack of quantification of the peptides in VOO. Another limitation is that we only analysed the water-soluble peptide fraction of VOO, so it is quite likely that there are other peptide sequences with biological activity that have yet to be identified. At present, we are investigating the effect of the in vitro digestion of VOO peptides on their ACE-inhibitory activity. The antihypertensive and antioxidant effects of VOO endogenous peptides are also being tested in vivo by using the spontaneously hypertensive rat model of hypertension. This animal model allows for investigation of the long- and short-term effects of bioactive peptides on blood pressure, as well as use of the biomarkers of oxidation to explore antioxidant effects. Those results should corroborate the antihypertensive and antioxidant effects in vivo of VOO peptides.

3. Materials and Methods

3.1. Plant Material and Extraction of Olive Oil

Olive fruits (*Olea europea* L. variety Picual) were hand-picked from healthy olive trees in the province of Granada (Spain). The olives used for extraction of oil were collected at the beginning of the maturation stage with a ripening index 5, according to the scale described in [73], when olives have black skin and white pulp. Extraction of the olive oil was carried out using a laboratory scale olive oil extraction system (Abencor, MC2 Ingeniería y Sistemas SL, Sevilla, Spain), as previously described by [74]. Filtration of the obtained olive oil was always avoided.

3.2. Extraction and Fractionation of VOO Peptides

Olive oil peptides were extracted from VOO, as described in [11]. In short, peptides were precipitated with a mixture of cold acetone:hexane (1:1) and the mixture was then centrifuged at 10,000 g for 15 min at 4 °C. The supernatant was discarded, and the precipitates were pooled and desiccated. Milli-Q water was used to solubilise the peptides with the aid of sonication, followed by centrifugation as above. The solubilised peptides were then subjected to gel filtration chromatography using fast protein liquid chromatography (FPLC) as described in [35]. The fractions containing molecular masses ranging from 1600 to 700 were selected. The fractions were pooled, then dried by using a rotary evaporator and stored at −80 °C until further analysis.

3.3. LC-Orbitrap MS/MS Analysis of Peptide Fractions

The peptide fractions extracted from VOO described above were analysed by nanoscale liquid chromatography-Orbitrap coupled with tandem mass spectrometry (nanoLC-Orbitrap-MS/MS) and de novo sequencing. For this, the dried extract described above was dissolved with 1 mL of Milli-Q water, and then it was diluted 10-fold with 0.1% formic acid prepared in Milli-Q water. Using nanoLC-Orbitrap MS/MS in duplicates, 5 µL of samples (containing 0.3 µg of proteins) were analysed. The peptides were separated onto a C-18 reversed phase nano-column (75 µm I.D.; 15 cm length; 3 µm particle diameter, Nikkyo Technos Co. LTD, Japan) coupled to a trap nano-column (100 µm ID; 2 cm length; 5 µm particle diameter, Thermo Fisher Scientific, Waltham, Massachussets, USA). The chromatographic separation was performed with 0.1% formic acid in Milli-Q water (phase A) and 0.1% formic acid in acetonitrile (phase B), using the following gradient: 0 to 5% B in 2 min, 5 to
35% of B in 30 min, 35 to 75% B in 20 min and 75 to 95% B in 5 min, maintained for 10 min. A flow rate of 300 nl/min was used to elute peptides for real time ionisation and peptide fragmentation on an LTQ-Orbitrap Velos Pro mass spectrometer (Thermo Fisher). An enhanced Fourier-transform MS/MS-resolution spectrum (resolution = 30,000 full width at half maximum) was obtained, followed by a data dependent MS/MS scan. The data dependent MS/MS event consists of collision-induced dissociation fragmentation (35% normalized collision energy) and ion trap-MS/MS acquisition from the most intense ten parent ions with a charge state rejection of +1 (Z = 1) and dynamic exclusion of 0.5 min, which is typically used for peptide identification. Interferences with other possible organic compounds were reduced by selecting only precursor ions with a minimum charge of +2 (Z = 2) or higher.

3.4. Peptide and Protein Identification by de Novo Sequencing and Database Search

Peaks X Pro (Bioinformatics Solutions Inc., Waterloo, ON, Canada) software was used for the treatment of the raw mass spectrometry data obtained by the nanoLC-Orbitrap-MS/MS analysis. De novo sequencing and Peaks database searching-based protein identification (Peaks DB) were used to identify the most likely peptide sequence that matched the resulting spectra obtained from the LC-MS/MS analysis [38]. The parameters used for the analysis include parent mass error tolerance: 10.0 ppm; fragment mass error tolerance: 0.5 Da; precursor mass search type: monoisotopic; enzyme: none; variable modifications: oxidation of methionine. De novo peptide sequencing results obtained by Peaks are confirmed by local confidence scores at the amino acid level. The local confidence score ranges from 0% to 99%, showing how confidently the algorithm considers a particular amino acid in the sequence as the correct assignment. The results were filtered by using the average local confidence (ALC) parameter, which is the average of the local confidence score of all the amino acids in the sequence. An ALC value above 90% (over this value, the sequence prediction is great, according to Peaks) was used to filter the results obtained from de novo sequencing analysis.

Database searches were carried out with Peaks DB algorithm, using the available *Olea europaea* (cv. Farga) genome database [75], containing 55,595 protein-coding genes, which can be downloaded at [76]. Peptide-spectrum matches were filtered by peptide $-10\log P$ score. This parameter is calculated for every peptide-precursor spectrum match reported by Peaks DB and indicates the statistical significance of the peptide-precursor spectrum match (the quality of the match). The score is derived from the $p$-value, defined by Peaks as the probability that a false identification in the database search achieves the same, or better, matching score. For example, a $-10\log P$ score of 20 (suggested by Peaks as a starting value to filter peptide-spectrum matches) is equivalent to a $p$-value of 0.01, which indicates that the probability of the peptide amino acid sequence being false is $\leq 1\%$. According to Peaks, a $-10\log P$ score > 30 indicates a peptide sequence identified with high confidence [77,78]. In our study, we used a $-10\log P$ score threshold of 30 ($p = 0.001$) to filter for peptide-spectrum matches. Peptide identifications were accepted if they appeared in at least two individual samples. Identified proteins were also filtered using a $-10\log P$ score of 30. The protein score is calculated as the weighted sum of the $-10\log P$ scores of the protein’s supporting peptides. Relative abundance of the peptides was calculated by Peaks based on peptide features detected from LC-MS/MS data by integrating the area under the curve (label-free quantification). Protein abundance was calculated by the addition of areas obtained from the supporting peptides. The protein sequences retrieved from the database search were subjected to NCBI BLAST-P search [79] to look for significant alignments and similarities with other previously identified proteins present in their databases (including *Olea europaea*). Protein identification matches of the highest quality, with an identity percentage of 100% and a cover percentage >95%, were reported.
3.5. Biological Activity Prediction of VOO Peptides and Peptide Selection

Biological activities of the peptides obtained by de novo sequencing and database search were explored by using the BIOPEP-UWM database of bioactive peptides [80]. This database contains referenced data from 4399 bioactive peptides (as of December 2021), including 1064 inhibitors of ACE and 756 antioxidant peptides [81]. Potential biological activity of the peptide sequence is calculated by the database by using parameters A and B. Parameter A is the number of sequences with the previously reported activity divided by total number of amino acid residues (N) of the peptide sequence. Parameter B is the potential biological activity of the peptide ($\mu$M$^{-1}$) calculated using published data of the activity of sequence motif(s) present in the peptide [82]. The action of digestive enzymes on endogenous peptides identified by Peaks DB and de novo sequencing was studied in silico. Biological activity of the peptide fragments originated from the proteolytic activity of pepsin, trypsin and chymotrypsin was investigated by using the BIOPEP database. A selection of potentially active peptides was carried out for subsequent in vitro studies. The criteria we used for the peptide selection were: water solubility (% of hydrophobicity), ACE-inhibitor and antioxidant activity predicted by BIOPEP (confirmed by activity of the proteolytic fragments originated by digestive enzymes), peptide relative abundance, the presence of one or more hydrophobic or positively charged amino acids within the three amino acids closest to the C-terminal position [83], and the presence of one or more cysteine amino acids in the sequence.

3.6. Peptide Synthesis

Selected peptides were synthesised by CASLO ApS (Scion Denmark Technical University, Lyngby, Denmark). The purity and molecular mass of the synthesised peptides were certified by analytical HPLC and mass spectrometry (MALDI-TOF, not shown). The purity of the synthetic peptides was 97.1% on average (range 91.9–99.3%). All peptide matches were approved by the supplier. The peptides were used to investigate their antioxidant and ACE-inhibitory activities.

3.7. Peptide Concentration Determination

The total peptide concentrations in the olive oil extracts were determined by fluorescence using a protein quantification kit (FluoroProfile, Sigma-Aldrich, Saint Louis, Missouri, USA). BSA was used as standard solution. Fluorometric quantification was carried out to 530 nm and 630 nm as excitation and emission wavelengths, respectively.

3.8. Determination of Angiotensin-Converting Enzyme Inhibitory Activity

The ACE-inhibitory activity of the synthetic peptides was determined according to the method described in [84], with some modifications. This assay is based on the ability of ACE to hydrolyse the substrate o-aminobenzoylglycyl-p-nitrophenylalanyl-proline (Abz-Gly-Phe-(NO$_2$)-Pro, Bachem Feinchemikalien, Bubendorf, Switzerland), producing the fluorescent product o-aminobenzoylglycine (Abz-Gly). Reagents used include: buffer A: 150 mM Tris-HCl buffer (pH 8.3), with 0.1 $\mu$M ZnCl$_2$; buffer B: 150 mM de Tris-HCl buffer (pH 8.4), with 1125 mM NaCl; ACE solution (stock): rabbit-lung ACE (E.C.3.4.15.1., Sigma-Aldrich), dissolved in buffer A containing 50% glycerol to make an enzyme concentration of 1 U/mL. This solution was diluted 1/20 with buffer A to obtain the working solution (50 mU/mL), which was prepared fresh every day to conduct the experiment. The substrate solution (Abz-Gly-Phe(NO$_2$)-Pro) was dissolved in buffer B to a final concentration of 0.45 mM. This solution was also prepared every day before its use and was protected from light and kept at 4 °C. The assay was carried out using a fluorescence technique. Black polystyrene plates of 96 wells (Thermo Scientific, Waltham, Massachusetts, USA) were used. The wells contained the following reaction solutions: control = 50 $\mu$L of Milli-Q water and 50 $\mu$L of ACE solution; blank = 50 $\mu$L of Milli-Q water and 50 $\mu$L of buffer A; sample = 50 $\mu$L of sample and 50 $\mu$L of ACE solution; sample blank = 50 $\mu$L of sample and 50 $\mu$L of buffer A. The enzymatic reaction was initiated by adding 200 $\mu$L (final volume in
each well 300 µL) of substrate solution, and the plate was immediately mixed and incubated at 37 °C in a VICTORX5 fluorometer (PerkinElmer, USA). The fluorescence generated was measured after 30 min using 355 and 420 nm as excitation and emission wavelengths, respectively. The ACE-inhibitory activity of each sample was determined in triplicate. The ACE-inhibitory activity was calculated using the following formula:

\[ \text{ACE inhibitory activity (\%)} = \frac{(\text{FC} - \text{FB}) - (\text{FS} - \text{FBs})}{\text{FC} - \text{FB}} \times 100 \]

where FC (control) is the fluorescence emitted after the action of ACE on the substrate, without inhibitor (i.e., sample); FB (blank) is the fluorescence emitted by the substrate; FS (sample) is the fluorescence emitted after the action of ACE on the substrate, with inhibitor sample; and FBs (blank sample) are the fluorescences emitted by the substrate and the sample.

The ACE-inhibitory activity is expressed as IC\textsubscript{50}, which is the concentration of inhibitor required to inhibit the activity of ACE by 50%.

3.9. Determination of the Antioxidant Activity

The antioxidant capacity of the synthetic peptides was assessed by using the ABTS \([2,2’-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)]\) radical cation decolorization (scavenging) assay, as described in [85]. Calibration curves of the antioxidant Trolox (0–1 mM) were used as standards. All ABTS assays were carried out at least three times and in triplicate at each concentration of the Trolox standards and peptide samples. The values of antioxidant capacity of the synthetic peptides were expressed in TEAC (Trolox Equivalent Antioxidant Capacity). TEAC is defined as the millimolar concentration of a Trolox solution with equivalent antioxidant potential to a 1 mM concentration of the compound under investigation [70].

3.10. Statistical Analysis

Data are expressed as means ± standard error of the mean (SEM). Differences of \(p<0.05\) between the groups were considered significant. SPSS statistical software version 23.0 was used for the statistical analysis (SPSS, Chicago, IL, USA).

4. Conclusions

We identified 19 new peptides, as well as their proteins sources, and eight de novo sequencing peptides in a water-soluble extract of VOO. The peptide sequences were predicted to possess different types of bioactivity. Synthetic peptides VCGEAFGKA, NALLCSNS, CPANGFY, CCYSVY and DCHYFL possessed strong ACE-inhibitory and antioxidant activities in vitro. More research is needed to clarify the potential role of antioxidant peptides in VOO quality and their biological effects in humans.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms23031712/s1.

Author Contributions: Conceptualization, Eduardo Lopez-Huertas (E.L.-H.); methodology, E.L.-H. and Juan M. Alcaide-Hidalgo (J.M.A.-H.); software, E.L.-H.; validation, E.L.-H. and J.M.A.-H.; formal analysis, E.L.-H.; investigation, E.L.-H. and J.M.A.-H.; resources, E.L.-H.; data curation, E.L.-H.; writing—original draft preparation, E.L.-H.; writing—review and editing, E.L.-H.; visualization, E.L.-H.; supervision, E.L.-H.; project administration, E.L.-H.; funding acquisition, E.L.-H. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by European Regional Development Funds under the signed agreement between MINECO and CSIC for the realization of the RECUPERA 2020 project.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available on request made to the corresponding author.

Acknowledgments: The authors would like to express their gratitude to Rafael Hueso and Justa M. Amaro for their skilful technical assistance.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Visioli, F.; Franco, M.; Toledo, E.; Luchsinger, J.; Willett, W.C.; Hu, F.B.; Martinez-Gonzalez, M.A. Olive oil and prevention of chronic diseases: Summary of an international conference. Nutr. Metab. Cardiovasc. Dis. 2018, 28, 649–656. [CrossRef] [PubMed]
2. Blekas, G.; Tsimidou, M.; Boskou, D. Olive Oil Composition, 2nd ed.; American Oil Chemists’ Society, Ed.; AOCS Press: Urbana, IL, USA, 2006; pp. 42–72.
3. Brenes, M.; Garcia, A.; Garcia, P.; Rios, J.J.; Garrido, A. Phenolic compounds in Spanish olive oils. J. Agric. Food Chem. 1999, 47, 3535–3540. [CrossRef] [PubMed]
4. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA). Scientific Opinion on the substantiation of health claims related to polyphenols in olive and protection of LDL particles from oxidative damage (ID 1333, 1638, 1639, 1696, 2865), maintenance of normal blood HDL-cholesterol concentrations (ID 1639), maintenance of normal blood pressure (ID 3781), anti-inflammatory properties (ID 1882), contributes to the upper respiratory tract health (ID 3468), can help to maintain a normal function of gastrointestinal tract (3779), and contributes to body defences against external agents (ID 3467) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. ESHA J. 2011, 9, 2033–2057.
5. Montealegre, C.; Esteve, C.; Garcia, M.C.; Garcia-Ruiz, C.; Marina, M.L. Proteins in olive fruit and oil. Crit. Rev. Food Sci. Nutr. 2014, 54, 611–624. [CrossRef]
6. Liao, W.; Sun, G.; Xu, D.; Wang, Y.; Lu, Y.; Sun, J.; Xia, H.; Wang, S. The Blood-Pressure-Lowering Effect of Food-Protein-Derived Peptides: A Meta-Analysis of Recent Clinical Trials. Foods 2021, 10, 2316. [CrossRef]
7. Cruz-Huerta, E.; Fernandez-Tome, S.; Arques, M.C.; Amigo, L.; Recio, I.; Clemente, A.; Hernandez-Ledesma, B. The protective role of the Bowman-Birk protease inhibitor in soybean lunasin digestion: The effect of released peptides on colon cancer growth. Food Funct. 2015, 6, 2626–2635. [CrossRef]
8. Tornatore, L.; Sandomenico, A.; Raimondo, D.; Low, C.; Roccì, A.; Tralau-Stewart, C.; Capece, D.; D’Andrea, D.; Bua, M.; Boyle, E.; et al. Cancer-selective targeting of the NF-κB survival pathway with GADD45b/MKK7 inhibitors. Cancer Cell 2014, 26, 495–508. [CrossRef]
9. Jang, A.; Jo, C.; Kang, K.-S.; Lee, M. Antimicrobial and human cancer cell cytotoxic effect of synthetic angiotensin-converting enzyme (ACE) inhibitory peptides. Food Chem. 2008, 107, 327–336. [CrossRef]
10. Pak, V.V.; Koo, M.S.; Kasymova, T.D.; Kwon, D.Y. Isolation and identification of peptides from soy 11S-globulin with hypocholesterolemic activity. Chem. Nat. Compd. 2005, 41, 710–714. [CrossRef]
11. Lammi, C.; Zanoni, C.; Scigliuolo, G.M.; D’Amato, A.; Arnoldi, A. Lupin peptides lower low-density lipoprotein (LDL) cholesterol through an up-regulation of the LDL receptor/sterol regulatory element binding protein 2 (SREBP2) pathway at HepG2. J. Agric. Food Chem. 2014, 62, 7151–7159. [CrossRef]
12. Kagawa, K.; Matsutaka, H.; Fukuhama, C.; Fujino, H.; Okuda, H. Suppressive effect of globin digest on postprandial hyperlipidemia in male volunteers. J. Nutr. 1998, 128, 56–60. [CrossRef]
13. Chen, H.M.; Muramoto, K.; Yamauchi, F.; Fujimoto, K.; Nokihara, K. Antioxidative properties of histidine-containing peptides designed from peptide fragments found in the digests of a soybean protein. J. Agric. Food Chem. 1996, 44, 49–53. [CrossRef]
14. Rival, S.G.; Fornaroli, S.; Boeriu, C.G.; Wickers, H.J. Caseins and casein hydrolysates: Lipoxygenase inhibitory properties. J. Agric. Food Chem. 2001, 49, 287–294. [CrossRef]
15. Wang, Q.; Li, W.; He, Y.; Ren, D.; Kow, F.; Song, L.; Xingju, Y. Novel antioxidative peptides from the protein hydrolysate of oysters (Crassostrea talienwhanensis). Food Chem. 2014, 145, 991–996. [CrossRef]
16. Kwon, D.Y.; Daily, J.W.; III, Kim, H.J.; Park, S. Antidiabetic effects of fermented soybean products on type 2 diabetes. Nutr. Res. 2010, 30, 1–13. [CrossRef]
17. Lammi, C.; Zanoni, C.; Arnoldi, A. Three peptides from soy glycmin modulate glucose metabolism in human hepatic HepG2 cells. Int. J. Mol. Sci. 2015, 16, 27362–27370. [CrossRef]
18. Cam, A.; de Mejia, E.G. RGD-peptide lunasin inhibits Akt-mediated NF-κappaB activation in human macrophages through interaction with the alphaVbeta3 integrin. Mol. Nutr. Food Res. 2012, 56, 1569–1581. [CrossRef]
19. Diaz, V.P.; Bringe, N.A.; de Mejia, E.G. Peptides in pepsin-pancreatin hydrolysates from commercially available soy products that inhibit lipopolysaccharide-induced inflammation in macrophages. Food Chem. 2014, 152, 423–431. [CrossRef]
20. Yoshikawa, M.; Kishi, K.; Takahashi, M.; Watanabe, A.; Miyamura, T.; Yamazaki, M.; Chiba, H. Immunostimulating peptide derived from soybean protein. Ann. N. Y. Acad. Sci. 1993, 685, 375–376. [CrossRef]
21. Singh, B.P.; Vij, S.; Hati, S. Functional significance of bioactive peptides derived from soybean. Peptides 2014, 54, 171–179. [CrossRef]
22. Qian, Z.Y.; Jolles, P.; Migliore-Samour, D.; Schoentgen, F.; Fiat, A.M. Sheep kappa-casein peptides inhibit platelet aggregation. Biochim. Biophys. Acta 1995, 1244, 411–417. [CrossRef]
23. Chabance, B.; Jolles, P.; Izquierdo, C.; Mazoyer, E.; Francoual, C.; Drouet, L.; Fiat, A.M. Characterization of an antithrombotic peptide from kappacasein in newborn plasma after milk ingestion. Br. J. Nutr. 1995, 73, 583–590. [CrossRef] [PubMed]

24. Pedersen, N.L.; Nagain-Domaine, C.; Mahe, S.; Chariot, J.; Roze, C.; Tome, D. Caseinomacropeptide specifically stimulates exocrine pancreatic secretion in the anesthetized rat. Peptides 2000, 21, 1527–1535. [CrossRef]

25. Nishi, T.; Hara, H.; Asano, K.; Tomita, F. The soybean beta-conglycinin beta 51–63 fragment suppresses appetite by stimulating cholecystokinin release in rats. J. Nutr. 2003, 133, 2537–2542. [CrossRef]

26. Ohinata, K.; Agui, S.; Yoshikawa, M. Soymorphins, novel mu opioid peptides derived from soy beta-conglycinin beta-subunit, have anxiolytic activities. Biosci. Biotechnol. Biochem. 2007, 71, 2618–2621. [CrossRef]

27. Kaneko, K.; Iwasaki, M.; Yoshikawa, M.; Ohinata, K. Orally administered soymorphins, soy-derived opioid peptides, suppress feeding and intestinal transit via gut mu(1)-receptor coupled to 5-HT(1A), D(2), and GABA(B) systems. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 299, G799–G805. [CrossRef]

28. World Health Organisation. A Global Brief on Hypertension. Silent Killer, Global Public Health Crisis; Document number WHO/DCO/WHD/2013.2; WHO Press: Geneva, Switzerland, 2013.

29. Chobanian, A.V.; Bakris, G.L.; Black, H.R.; Cushman, W.C.; Green, L.A.; Izzo, J.L., Jr.; Jones, D.W.; Materson, B.J.; Oparil, S.; Wright, T.J., Jr.; et al. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003, 289, 2560–2572.

30. Saadi, S.; Saarit, N.; Anwar, F.; Hamid, A.A.; Mohd Ghazali, H. Recent advances in food biopeptides: Production, biological functionalities and therapeutic applications. Biotechnol. Adv. 2015, 33, 80–116. [CrossRef]

31. Escudero, E.; Mora, L.; Fraser, P.D.; Aristoy, M.C.; Arihara, K.; Toldrá, F. Purification and Identification of antihypertensive peptides in Spanish dry-cured ham. J. Proteom. 2013, 78, 499–507. [CrossRef]

32. Mandal, S.M.; Bharti, R.; Porto, W.F.; Gauri, S.S.; Mandal, M.; Franco, O.L.; Ghosh, A.K. Identification of multifunctional peptides from human milk. Peptides 2014, 56, 84–93. [CrossRef]

33. Fekete, A.A.; Givens, D.I.; Lovegrove, J.A. Casein-derived lactotripeptides reduce systolic and diastolic blood pressure in a meta-analysis of randomised clinical trials. Nutrients 2015, 7, 659–681. [CrossRef]

34. Daliri, E.B.; Lee, B.H.; Oh, D.H. Current trends and perspectives of bioactive peptides. Crit. Rev. Food Sci. Nutr. 2018, 58, 2273–2284. [CrossRef]

35. Alcaide-Hidalgo, J.M.; Margalef, M.; Bravo, F.I.; Muguerza, B.; López-Huertas, E. Virgin olive oil (unfiltered) extract contains peptides and possesses ACE inhibitory and antihypertensive activity. Clin. Nutr. 2020, 39, 1242–1249. [CrossRef]

36. Alcaide-Hidalgo, J.M.; Romero, M.; Duarte, J.; López-Huertas, E. Antihypertensive Effects of Virgin Olive Oil (Unfiltered) Low Molecular Weight Peptides with ACE Inhibitory Activity in Spontaneously Hypertensive Rats. Nutrients 2020, 12, 271. [CrossRef]

37. Herregods, G.; Van Camp, J.; Morel, N.; Ghesquiere, B.; Gevaert, K.; Vercruysse, L.; Dierckx, S.; Quanten, E.; Smagghe, G. Angiotensin I-Converting Enzyme Inhibitory Activity of Gelatin Hydrolysates and Identification of Bioactive Peptides. J. Agric. Food Chem. 2011, 59, 552–558. [CrossRef]

38. Ma, S.; Zhang, K.; Hendrie, C.; Liang, C.; Li, M.; Doherty-Kirby, A.; Lajoie, G. PEAKS: Powerful Software for Peptide De Novo Sequencing by MS/MS. Rapid. Commun. Mass Spectrom. 2003, 17, 2337–2342. [CrossRef]

39. Natesh, R.; Schwager, S.L.U.; Sturrock, E.D.; Acharya, K.R. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003, 421, 551–554. [CrossRef]

40. Erdmann, K.; Cheung, B.W.; Schröder, H. The possible roles of food-derived bioactive peptides in reducing the risk of cardiovascular disease. J. Nutr. Biochem. 2008, 19, 643–654. [CrossRef]

41. Elias, R.J.; Kellerby, S.S.; Decker, E.A. Antioxidant Activity of Proteins. Crit. Rev. Food Sci. Nutr. 2008, 48, 430–441. [CrossRef] [PubMed]

42. BLAST: Basic Local Alignment Search Tool. Available online: https://blast.ncbi.nlm.nih.gov/Blast.cgi (accessed on 21 November 2021).

43. Alché, J.D.; Jiménez-López, J.C.; Wang, W.; Castro-López, A.J.; Rodriguez-García, M.I. Biochemical characterization and cellular localization of 115 type storage proteins in olive (Olea europaea L.) seeds. J. Agric. Food Chem. 2006, 54, 5562–5570. [CrossRef]

44. Castro, A.J.; Lima-Cabello, E.; Alché, J.D. Identification of seed storage proteins as the major constituents of the extra virgin olive oil proteome. Food Chem. X 2020, 7, 100099. [CrossRef] [PubMed]

45. The UniProt Consortium. UniProt: A worldwide hub of protein knowledge. Nucleic Acids Res. 2019, 47, D506–D515. [CrossRef] [PubMed]

46. Wang, Y.; Bouwmeester, K. I-type lectin receptor kinases: New forces in plant immunity. PloS Pathog. 2017, 13, e1006433. [CrossRef] [PubMed]

47. Kuang, H.; Wei, F.; Marano, M.R.; Wirtz, U.; Wang, X.; Liu, J.; Shum, W.P.; Zaborsky, J.; Tallon, L.J.; Rensink, W.; et al. The R1 resistance gene cluster contains three groups of independently evolving, type I R1 homologues and shows substantial structural variation among haplotypes of Solanum demissum. Plant J. 2005, 44, 37–51. [CrossRef] [PubMed]

48. Tadini, L.; Pessaresi, P.; Kleine, T.; Rossi, F.; Guljamow, A.; Sommer, F.; Mühlhaus, T.; Schrola, M.; Masiero, S.; Pribil, M.; et al. GUN1 Controls Accumulation of the Plastid Ribosomal Protein S1 at the Protein Level and Interacts with Proteins Involved in Plastid Protein Homeostasis. Plant Physiol. 2016, 170, 1817–1830. [CrossRef] [PubMed]
49. Li, F.; Fan, G.; Lu, C.; Xiao, G.; Zou, C.; Kohel, R.J. Genome sequence of cultivated upland cotton (Gossypium hirsutum TM-1) provides insights into genome evolution. Nat. Biotechnol. **2015**, *33*, 524–530. [CrossRef]

50. Breitsprecher, D.; Kiesewetter, A.K.; Linkner, J.; Urbanke, C.; Resch, G.P.; Small, J.V.; Faix, J. Clustering of VASP actively drives WH2 domain-mediated actin filament elongation. *EMBO J.* **2008**, *27*, 2943–2954. [CrossRef]

51. Toledo-Ortiz, G.; Huq, E.; Quail, P.H. The Arabidopsis basic/helix-loop-helix transcription factor family. *Plant Cell* **2003**, *15*, 1749–1770. [CrossRef]

52. Lopez-Moya, F.; Suarez-Fernandez, M.; Lopez-Llorca, L.V. Molecular mechanisms of chitosan interactions with fungi and plants *Int. J. Mol. Sci.* **2019**, *20*, 232. [CrossRef]

53. Jha, S.; Taschler, U.; Domenig, O.; Poglitsch, M.; Bourgeois, B.; Pollheimer, M.; Frank, S.; Madl, T.; et al. Dipetidyl peptidase 3 modulates the renin-angiotensin system in mice. *J. Biol. Chem.* **2020**, *295*, 13711–13723. [CrossRef]

54. Breitsprecher, D.; Kiesewetter, A.K.; Linkner, J.; Urbanke, C.; Resch, G.P.; Small, J.V.; Faix, J. Clustering of VASP actively drives WH2 domain-mediated actin filament elongation. *EMBO J.* **2008**, *27*, 2943–2954. [CrossRef]

55. Deacon, C.F. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. *Nat. Rev. Endocrinol.* **2020**, *16*, 642–653. [CrossRef]

56. Sentandreu, M.A.; Toldra, F. Evaluation of ACE inhibitory activity of dipeptides generated by the action of porcine muscle dipetidyl peptidases. *Food Chem.* **2007**, *101*, 1629–1633. [CrossRef]

57. Yano, S.; Suzuki, K.; Funatsu, G. Isolation from alpha-zein of thermolysin peptides with angiotensin I-converting enzyme inhibitory activity. *Biosci. Biotechnol. Biochem.* **1994**, *58*, 1192–1197. [CrossRef]

58. Kou, X.H.; Gao, J.; Xue, Z.H.; Zhang, Z.J.; Wang, H.; Wang, X. Purification and identification of antioxidant peptides from chickpea (*Cicer arietinum* L.) albumin hydrolysates. *LWT-Food Sci. Technol.* **2013**, *50*, 591–598. [CrossRef]

59. Kitts, D.D.; Weiler, K. Bioactive proteins and peptides from food sources. *Curr. Pharm. Des.* **2003**, *9*, 1309–1323. [CrossRef] [PubMed]

60. Saito, Y.; Wanezaki, K.; Kawato, A.; Imayasu, S. Structure and activity of angiotensin I converting enzyme inhibitory peptides. *Biosci. Biotechnol. Biochem.* **2004**, *68*, 2148–2152. [CrossRef] [PubMed]

61. Mendis, E.; Rajapakse, N.; Kim, S.-K. Antioxidant properties of a radical-scavenging peptide purified from enzymatically prepared fish skin gelatin hydrolysate. *J. Agric. Food Chem.* **2005**, *53*, 581–587. [CrossRef] [PubMed]

62. Erdmann, K.; Grosser, N.; Schipporeit, K.; Schroder, H. The ACE inhibitory dipeptide Met-Tyr diminishes free radical formation. *Int. J. Mol. Sci.* **2020**, *21*, 4837–4856. [CrossRef] [PubMed]

63. Mateos, R.; Dominguez, M.M.; Espartero, J.L.; Cert, A. Antioxidant effect of phenolic compounds, α-tocopherol, and other minor components in virgin olive oil. *J. Agric. Food Chem.* **2003**, *51*, 7170–7175. [CrossRef]

64. Kitts, D.D.; Weiler, K. Bioactive proteins and peptides from food sources. *Curr. Med. Chem.* **2005**, *12*, 1905–1919. [CrossRef] [PubMed]

65. Mendis, E.; Rajapakse, N.; Kim, S.-K. Antioxidant properties of a radical-scavenging peptide purified from enzymatically prepared fish skin gelatin hydrolysate. *J. Agric. Food Chem.* **2005**, *53*, 581–587. [CrossRef] [PubMed]

66. Jha, S.; Taschler, U.; Domenig, O.; Poglitsch, M.; Bourgeois, B.; Pollheimer, M.; Frank, S.; Madl, T.; et al. Dipetidyl peptidase 3 modulates the renin-angiotensin system in mice. *J. Biol. Chem.* **2020**, *295*, 13711–13723. [CrossRef]

67. Kou, X.H.; Gao, J.; Xue, Z.H.; Zhang, Z.J.; Wang, H.; Wang, X. Purification and identification of antioxidant peptides from chickpea (*Cicer arietinum* L.) albumin hydrolysates. *LWT-Food Sci. Technol.* **2013**, *50*, 591–598. [CrossRef]

68. Ryan, J.T.; Ross, R.P.; Bolton, D.; Fitzgerald, G.F.; Stanton, C. Bioactive peptides from muscle sources: Meat and fish. *Nutrients* **2011**, *3*, 765–791. [CrossRef]

69. Maestri, E.; Marmirollo, M.; Marmirollo, N. Bioactive peptides in plant-derived foodstuffs. *J. Proteom.* **2016**, *147*, 140–155. [CrossRef]

70. Rice-Evans, C.; Miller, N.J. Total antioxidant status in plasma and body fluids. *Bioresour. Technol.* **1994**, *48*, 279–293. [CrossRef]

71. Mateos, R.; Dominguez, M.M.; Espartero, J.L.; Cert, A. Antioxidant effect of phenolic compounds, α-tocopherol, and other minor components in virgin olive oil. *J. Agric. Food Chem.* **2003**, *51*, 7170–7175. [CrossRef]

72. López-Huertas, E.; Palma, J.M. Changes in Glutathione, Ascorbate, and Antioxidant Enzymes during Olive Fruit Ripening. *J. Agric. Food Chem.* **2003**, *51*, 7170–7175. [CrossRef]

73. López-Huertas, E.; Palma, J.M. Changes in Glutathione, Ascorbate, and Antioxidant Enzymes during Olive Fruit Ripening. *J. Agric. Food Chem.* **2003**, *51*, 7170–7175. [CrossRef]

74. Ryan, J.T.; Ross, R.P.; Bolton, D.; Fitzgerald, G.F.; Stanton, C. Bioactive peptides from muscle sources: Meat and fish. *Nutrients* **2011**, *3*, 765–791. [CrossRef]

75. Maestri, E.; Marmirollo, M.; Marmirollo, N. Bioactive peptides in plant-derived foodstuffs. *J. Proteom.* **2016**, *147*, 140–155. [CrossRef]

76. Lopez-Huertas, E.; Lozano-Sánchez, J.; Segura-Carretero, A. Olive oil varieties and ripening stages containing the antioxidants hydroxytyrosol and derivatives in compliance with EFSA health claim. *Food Chem.* **2020**, *324*, 128291. [CrossRef]

77. Wang, X.; Xue, Z.H.; Zhang, Z.J.; Wang, H.; Wang, X. Purification and identification of antioxidant peptides from chickpea (*Cicer arietinum* L.) albumin hydrolysates. *LWT-Food Sci. Technol.* **2013**, *50*, 591–598. [CrossRef]

78. The olive Genome. Available online: <https://denovo.cnag.cat/olive> (accessed on 21 November 2021).

79. Zhang, J.; Xin, L.; Shan, B.; Chen, W.; Xie, M.; Yuen, D.; Zhang, W.; Zhang, Z.; Gilles, A.; Lajoie, G.A.; et al. Peaks DB: De novo sequencing assisted database search for sensitive and accurate peptide identification. *Mol. Cell Proteom.* **2012**, *11*, M111.010587. [CrossRef]

80. Peaks Team. Peaks X Pro user Manual. 2020. Available online: <www.bioinforn.com/user-manual/> (accessed on 21 November 2021).
80. Minkiewicz, P.; Dziuba, J.; Iwaniak, A.; Dziuba, M.; Darewicz, M. BIOPEP database and other programs for processing bioactive peptide sequences. *J. AOAC Int.* 2008, 91, 965–980. [CrossRef]

81. BIOPEP-UWM: Bioactive Peptides. Available online: https://biochemia.uwm.edu.pl/en/biopep-uwm-2/ (accessed on 21 November 2021).

82. Dziuba, J.; Iwaniak, A.; Minkiewicz, P. Computer-aided characteristics of proteins as potential precursors of bioactive peptides. *Polimery* 2003, 48, 50–53. [CrossRef]

83. Hernández-Ledesma, B.; del Mar Contreras, M.; Recio, I. Antihypertensive peptides: Production, bioavailability and incorporation into foods. *Adv. Colloid Interface Sci.* 2011, 165, 23–35. [CrossRef]

84. Sentandreu, M.A.; Toldrá, F. A fluorescence-based protocol for quantifying angiotensin-converting enzyme activity. *Nat. Protoc.* 2006, 1, 2423–2427. [CrossRef]

85. Re, R.; Pellegrini, N.; Protegente, A.; Pannala, A.; Yang, M.; Rice-Evans, C. Antioxidant activity applying an improved ABTS radical cation decolorization assay. *Free Rad. Biol. Med.* 1999, 26, 1231–1237. [CrossRef]